Latest News for: cld
Edit
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 ...
Nasdaq Globe Newswire 24 Jun 2026
Findings highlight RedTail’s potential to overcome historical ...
Edit
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit (Calidi Biotherapeutics Inc)
Public Technologies 24 Jun 2026
CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 superagonist ("IL-15 SA"), a known CD8⁺ T-cell, NK cell, and gamma delta (γδ) T-cell activator, in the TME.
Edit
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its ...
Nasdaq Globe Newswire 16 Jun 2026
Edit
The Eagle-Tribune
16 Jun 2026
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating
Edit
Building a GMP-Ready Cell Line Development Strategy from Day One – Part 1: The Risks of Splitting CLD & GMP Manufacturing (Abzena Ltd)
Public Technologies 15 Jun 2026
Edit
Prof. Frith Named to CLD Leadership Development Committee (Monmouth University Inc)
Public Technologies 06 May 2026
Danielle Frith, Ph.D., specialist professor in the Department of Special Education, has been selected to serve a three-year term on the Leadership Development Committee (LDC) for the Council for Learning Disabilities (CLD) Board of Trustees.
Edit
Hastings Tribune
21 Apr 2026
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting
Edit
CLD-401, an IL-15 superagonist gene medicine via redtail virotherapy, achieves sustained tumor eradication (Calidi Biotherapeutics Inc)
Public Technologies 21 Apr 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
- 1